Is compounded semaglutide the same as Ozempic or Wegovy?

No, and FDA treats the claim that it is as a warning sign. Its telehealth red-flag list names a company that "makes claims such as the compounded drug is the same as an FDA-approved drug." The approved products are reviewed medicines with a stated strength, a stated concentration, a titration schedule, a boxed warning and a device that sets the dose. A compounded preparation is made to order and, in FDA's words, "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." Some compounded product is not even the same active ingredient: FDA states that salt forms such as semaglutide sodium and semaglutide acetate "are different active ingredients than are used in the approved drugs."

Is compounded semaglutide still legal now the shortage is over?

The basis most of the market was built on has gone. Compounding a product that is essentially a copy of an approved drug is permitted while that drug is on FDA's shortage list; FDA determined the semaglutide injection shortage resolved on 21 February 2025, and its compounding page — current as of 1 April 2026 — states that "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list" and that for a state-licensed pharmacy or physician compounding under section 503A "the period of enforcement discretion (described below) has ended." FDA adds that it does not intend to act against a compounder who fills "four or fewer prescriptions" of an essentially-a-copy product in a calendar month, and that a documented prescriber determination of a significant difference for an identified individual patient takes a preparation outside the essentially-a-copy rule. Whether a particular pharmacy is operating within that is a question to put to the pharmacy.

What dose of compounded semaglutide should I take?

No label states one and this page will not supply a figure from anywhere else. What exists is the approved schedule for an approved product — Wegovy injection escalates 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg in 4 steps of 4 weeks, Ozempic stops at 2 mg weekly — and those belong to reviewed products, not to the molecule. Reading them across to a vial of unknown concentration is precisely the error FDA describes: it has adverse-event reports of patients "prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label", including "increasing the amount more quickly (titration schedule)". If you have been given a compounded vial, the only figures that apply to it are the ones on its own label and in your own prescription.

Why do people overdose on compounded semaglutide?

Because a vial does not set the dose and a pen does. The published poison-control case series (J Am Pharm Assoc 2023) reports three adverse drug events after incorrect administration, of which "Two patients self-administered 10-fold dosing errors" and "One patient reported dosing in milliliters and units rather than in milligrams." Its conclusion names the mechanism directly: "Vials of compounded semaglutide do not use safety features provided by prefilled manufactured pens and allow for large overdoses (e.g., 10-fold dosing errors). Use of syringes not intended for semaglutide contributes to the variability of dosing units (milliliters, units, milligrams), contributing to patient confusion." One of the three patients had received a vial and syringes with no pharmacist counselling on how to use them.

How many people have been harmed?

FDA publishes a count and immediately explains why it is a floor. As of May 31, 2026 the agency had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. It adds that "federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported", and that many of the reported events look like the ones seen with the approved products. There is no published denominator — nobody knows how many people took compounded semaglutide — so the number cannot be turned into a rate and is not turned into one here.

How much cheaper is compounded semaglutide?

This site does not publish that comparison, and the reason is that only one side of it is sourceable. CMS NADAC prices National Drug Codes, which is how a month of Ozempic can be stated as $1,079 and a month of Wegovy 2.4 mg as $1,415 in the file dated 2026-09-16. A compounded preparation has no NDC and no published acquisition cost. The advertised price of a telehealth subscription is a retail figure that bundles a consultation, shipping and a margin, and setting it against a pharmacy invoice price for a different product is not a like-for-like comparison of anything. The more useful point is that price is not among the grounds FDA names for using a compounded drug at all.

When is a compounded drug actually appropriate?

FDA answers this in one sentence: "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug." It elaborates that a compounded drug "might be appropriate if a patient's medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available." The second limb is the shortage route, which for semaglutide closed in 2025. The first is a genuine clinical route — an allergy to an excipient in the approved product is the classic example — and it requires a prescriber determination rather than a preference. FDA also advises obtaining a prescription from your doctor and filling it at a state-licensed pharmacy, and contacting the compounder or platform directly if anything about the label or the instructions is unclear.

Head to head

Brand vs Compounded Semaglutide

Not a cheaper version of the same medicine. One column below is filled from five FDA-approved labels; the other is empty in every cell where a dose, a strength or a schedule would go.

Reviewed September 2026

The short answer

Start with what exists and what does not. Semaglutide is approved in the United States in 5 distinct dosing schedules across three brand names, each with its own label, its own escalation, and its own maximum — 2 mg, 7.2 mg, 14 mg, 9 mg, 25 mg. Compounded semaglutide has no FDA label of any kind. No approved strength, no approved concentration, no approved titration schedule, and no regulator has reviewed any particular preparation for safety, effectiveness or quality before it was dispensed.

That is the FDA's own framing, not an editorial one: "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." The agency lists, among its warning signs for a telehealth platform, a company that "makes claims such as the compounded drug is the same as an FDA-approved drug".

The legal basis also changed and most pages answering this query have not updated. Compounding something that is otherwise essentially a copy of an approved drug is permitted while that drug is on FDA's shortage list. FDA declared the semaglutide injection shortage resolved on 21 February 2025, and its compounding page now states that "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list" and that for state-licensed pharmacies "the period of enforcement discretion (described below) has ended."

And the specific harm is documented rather than hypothetical. FDA has received "multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products", plus reports of prescribing "in doses beyond what is in the FDA-approved drug label… increasing the amount more quickly (titration schedule)". A poison-control case series found two patients who gave themselves ten times the intended dose. The mechanism is the missing device: a pen dials a dose, a vial and a syringe require arithmetic.

Brand semaglutide

Ozempic · Wegovy · Rybelsus

FDA-approved semaglutide, sold as five distinct products with five labelled dose ladders, five ceilings and a device that sets the dose.

Dosing protocol →

Compounded semaglutide

no brand name · sold as "semaglutide" by compounding pharmacies and telehealth platforms

A preparation made to order by a pharmacy. Not FDA-approved, not reviewed for safety, effectiveness or quality before it is dispensed, and carrying no approved strength or schedule.

Side by side

Every row carries how well supported it is. A claim that only reflects common practice is labelled as such rather than presented as fact.

Dimension	Brand semaglutide	Compounded semaglutide	Basis
Is there an FDA label?	Yes — 5 approved dosing schedules across Ozempic, Wegovy and Rybelsus	No — none, for any preparation	labelThe row every other row follows from. Approval is recorded in Drugs@FDA; the approved labels are Structured Product Labels on DailyMed with approval blocks reading NDA. There is no compounded semaglutide SPL and no compounded semaglutide application, because compounded drugs are not approved at all.
Approved indication	Type 2 diabetes, cardiovascular risk reduction, chronic kidney disease, weight reduction, noncirrhotic MASH — depending on the product	None — there is no indication to approve	labelEach brand carries its own indications and its own restrictions. A compounded preparation carries whatever the prescription says, which is a clinical decision rather than a reviewed one.
Labelled titration schedule	0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg — 4 escalation steps of 4 weeks each, printed as a table with week windows	None exists	labelWegovy injection's Table 1 states the weeks outright; Ozempic's escalation is conditional on glycaemic control with a stated minimum interval. Neither schedule transfers to a compounded product, because a schedule is a property of a reviewed product and not of a molecule. This page states no compounded titration.
Concentration	Fixed by the label — Wegovy pens are 0.25, 0.5 and 1 mg per 0.5 mL and 1.7, 2.4 and 7.2 mg per 0.75 mL	Set by whoever prepared it	labelThere is no approved concentration for compounded semaglutide, so the same volume drawn from two vials can be two different doses and nothing on the carton distinguishes them. This is why the units converters on this site require you to read your own vial and will not assume a strength.
How the dose is set	By the device — a dial or a single-dose pen built to deliver one stated amount	By the patient, with a syringe	labelThe Ozempic label instructs: "Always use the dose counter and the dose pointer to see how many mg you select. Do not set the dose by counting the number of clicks you hear." A vial has no dose counter. The published case series concluded that vials of compounded semaglutide "do not use safety features provided by prefilled manufactured pens and allow for large overdoses (e.g., 10-fold dosing errors)."
Boxed warning and prescribing information	Boxed warning for thyroid C-cell tumours, contraindications, ten or eleven Warnings and Precautions, pregnancy data, interactions	Whatever the compounder chooses to print	labelFDA reports being "aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label. In some cases, the compounding pharmacies identified on the labels of the products do not exist."
Missed dose instruction	Administer within 5 days of the missed dose; otherwise skip it.	Not stated by any label	labelA small thing that shows the shape of the difference. Ozempic states five days; Wegovy states a 48-hour rule. Both are the result of a review of the drug's pharmacokinetics in that product. A compounded vial comes with whatever instruction the pharmacy wrote, and there is no document to check it against.
In-use storage limit	Stated on the label — an Ozempic pen is 56 days after first use	FDA advises 28 days regardless of what the compounder says	labelFDA, verbatim: "Discard the vial within 28 days after the first use, even if medication remains in the vial. Do not continue using medication from the vial after 28 days, even if instructions from the compounder say the medication can be used for longer than 28 days." That second clause exists because compounder instructions sometimes say otherwise.
Legal basis for compounding it	Not applicable — it is an approved product	The shortage that permitted it was declared resolved on 21 February 2025	literatureFDA: "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list", and for a 503A pharmacy "the period of enforcement discretion (described below) has ended." FDA also states it does not intend to act against a compounder filling "four or fewer prescriptions" of an essentially-a-copy product in a calendar month. What a given pharmacy is doing lawfully today is a question for that pharmacy.
Is the active ingredient the same molecule?	Semaglutide, as reviewed	Sometimes a salt form, which FDA says is a different ingredient	literatureFDA, verbatim: "These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs. The agency does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and we are not aware of any lawful basis for their use in compounding."
Documented dosing errors	The device sets the dose, and FDA's dosing-error communication is not about it	FDA reports hospitalisations that may relate to dosing errors	literatureFDA, verbatim: "FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses of the drug."
Doses above the approved label	The ceiling is stated on the label and the pen cannot exceed it	FDA has adverse-event reports of exactly this	literatureFDA, verbatim: "the agency has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label. This could mean using more product in a single dose, taking doses more frequently or increasing the amount more quickly (titration schedule)."
Adverse events reported to FDA	Reportable to FDA by the manufacturer under federal law	990 reports as of May 31, 2026, and FDA says that is an undercount	literatureFDA: "federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported." The agency also notes that many reported events look like the ones seen with the approved products. The number is a floor, not a rate — no denominator is published.
What a pharmacy paid, per month	$1,079 Ozempic, $1,415 Wegovy 2.4 mg	No figure — and the absence is the point	literatureCMS NADAC, file dated 2026-09-16, prices National Drug Codes. A compounded preparation has no NDC, so there is no published acquisition cost for it and this site will not substitute the branded figure or a platform's advertised subscription. What can be said is that the difference in what you pay is not a difference between two versions of the same reviewed medicine.

label: Stated on the FDA label
guideline: Clinical practice guideline
literature: Published literature
practice: Common practice, not documented

Which one

Choose Brand semaglutide if

You want a dose someone has reviewed. That is the whole case, and for almost everyone it is the end of the discussion.
You want the device to do the arithmetic. A pen that dials a dose is the single feature the published case series identifies as missing when a ten-fold overdose happens.
You need a specific indication — chronic kidney disease in type 2 diabetes, noncirrhotic MASH, paediatric obesity from age 12. Those live on particular approved labels and nowhere else.
You want recourse. An approved product has a manufacturer, a lot number, mandatory adverse-event reporting and a recall mechanism. FDA has found compounded product bearing the names of pharmacies that do not exist.

Choose Compounded semaglutide if

An FDA-approved semaglutide product genuinely cannot meet your medical need. That is FDA's own standard, worded as "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug" — a documented intolerance of an inactive ingredient in the approved product is the textbook case.
Your prescriber has determined and documented that the compounded preparation "contains a change that produces a significant difference from the commercially available drug product" for you specifically. That documented determination is the one circumstance FDA's guidance names in which a compounded product is not treated as essentially a copy.

What is not on that list is price, and that omission is deliberate rather than squeamish. FDA's criterion for when compounding is appropriate is a medical need an approved drug cannot meet; cost is not among the grounds it names, and the shortage basis that carried the market until 2025 is gone. If you are being offered compounded semaglutide as a cheaper equivalent, the claim that it is equivalent is one FDA lists as a telehealth warning sign in those words. None of which means a compounded preparation will not raise your semaglutide level or that it is counterfeit by default — it means nobody has checked, the strength is whatever the pharmacy made it, and if the dose is wrong you will find out the way the patients in the case series did.

Frequently asked questions

Is compounded semaglutide the same as Ozempic or Wegovy?: No, and FDA treats the claim that it is as a warning sign. Its telehealth red-flag list names a company that "makes claims such as the compounded drug is the same as an FDA-approved drug." The approved products are reviewed medicines with a stated strength, a stated concentration, a titration schedule, a boxed warning and a device that sets the dose. A compounded preparation is made to order and, in FDA's words, "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." Some compounded product is not even the same active ingredient: FDA states that salt forms such as semaglutide sodium and semaglutide acetate "are different active ingredients than are used in the approved drugs."
Is compounded semaglutide still legal now the shortage is over?: The basis most of the market was built on has gone. Compounding a product that is essentially a copy of an approved drug is permitted while that drug is on FDA's shortage list; FDA determined the semaglutide injection shortage resolved on 21 February 2025, and its compounding page — current as of 1 April 2026 — states that "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list" and that for a state-licensed pharmacy or physician compounding under section 503A "the period of enforcement discretion (described below) has ended." FDA adds that it does not intend to act against a compounder who fills "four or fewer prescriptions" of an essentially-a-copy product in a calendar month, and that a documented prescriber determination of a significant difference for an identified individual patient takes a preparation outside the essentially-a-copy rule. Whether a particular pharmacy is operating within that is a question to put to the pharmacy.
What dose of compounded semaglutide should I take?: No label states one and this page will not supply a figure from anywhere else. What exists is the approved schedule for an approved product — Wegovy injection escalates 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg in 4 steps of 4 weeks, Ozempic stops at 2 mg weekly — and those belong to reviewed products, not to the molecule. Reading them across to a vial of unknown concentration is precisely the error FDA describes: it has adverse-event reports of patients "prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label", including "increasing the amount more quickly (titration schedule)". If you have been given a compounded vial, the only figures that apply to it are the ones on its own label and in your own prescription.
Why do people overdose on compounded semaglutide?: Because a vial does not set the dose and a pen does. The published poison-control case series (J Am Pharm Assoc 2023) reports three adverse drug events after incorrect administration, of which "Two patients self-administered 10-fold dosing errors" and "One patient reported dosing in milliliters and units rather than in milligrams." Its conclusion names the mechanism directly: "Vials of compounded semaglutide do not use safety features provided by prefilled manufactured pens and allow for large overdoses (e.g., 10-fold dosing errors). Use of syringes not intended for semaglutide contributes to the variability of dosing units (milliliters, units, milligrams), contributing to patient confusion." One of the three patients had received a vial and syringes with no pharmacist counselling on how to use them.
How many people have been harmed?: FDA publishes a count and immediately explains why it is a floor. As of May 31, 2026 the agency had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. It adds that "federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported", and that many of the reported events look like the ones seen with the approved products. There is no published denominator — nobody knows how many people took compounded semaglutide — so the number cannot be turned into a rate and is not turned into one here.
How much cheaper is compounded semaglutide?: This site does not publish that comparison, and the reason is that only one side of it is sourceable. CMS NADAC prices National Drug Codes, which is how a month of Ozempic can be stated as $1,079 and a month of Wegovy 2.4 mg as $1,415 in the file dated 2026-09-16. A compounded preparation has no NDC and no published acquisition cost. The advertised price of a telehealth subscription is a retail figure that bundles a consultation, shipping and a margin, and setting it against a pharmacy invoice price for a different product is not a like-for-like comparison of anything. The more useful point is that price is not among the grounds FDA names for using a compounded drug at all.
When is a compounded drug actually appropriate?: FDA answers this in one sentence: "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug." It elaborates that a compounded drug "might be appropriate if a patient's medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available." The second limb is the shortage route, which for semaglutide closed in 2025. The first is a genuine clinical route — an allergy to an excipient in the approved product is the classic example — and it requires a prescriber determination rather than a preference. FDA also advises obtaining a prescription from your doctor and filling it at a state-licensed pharmacy, and contacting the compounder or platform directly if anything about the label or the instructions is unclear.

Sources

Next steps

Which platforms dispense branded productEvery telehealth weight-loss provider we track, and whether they ship an approved pen or a compounded vial.Medical weight loss, start to finishEligibility, the first six months, monitoring, and what happens if you stop.

Other comparisons

Educational reference, not medical advice. Which medication suits you is a decision for your prescriber.